canada clinical guidance

HIV PrEP: eligibility, dosing options, baseline tests, and monitoring

A Canadian clinical summary of hiv prep: eligibility, dosing options, baseline tests, and monitoring, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Canadian guideline on HIV pre- and postexposure prophylaxis: 2025 update. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian HIV PrEP/PEP 2025

Source-attributed clinical priorities

  • Assess ongoing HIV acquisition risk and confirm a negative baseline HIV test before prescribing pre-exposure prophylaxis.
  • Check kidney function, hepatitis B status, pregnancy context, interactions and other STI prevention needs.
  • Use a Health Canada-supported regimen with scheduled HIV testing, safety monitoring and adherence support; coverage varies by jurisdiction.
  • Choose daily or event-driven prevention only for populations and regimens supported by current Canadian guidance.
sources for this section:Canadian HIV PrEP/PEP 2025

Practical assessment and management workflow

1
Assess ongoing sexual and injection-related exposure, goals and ability to use the regimen.
2
Confirm HIV-negative status with testing appropriate to recent exposure and symptoms.
3
Check kidney function, hepatitis B status, pregnancy and STI screening before initiation.
4
Repeat HIV testing, renal monitoring and STI care at the guideline-defined follow-up interval.
sources for this section:Canadian HIV PrEP/PEP 2025

Safety, red flags and urgent escalation

  • Do not start PrEP during possible acute HIV without urgent diagnostic assessment.
  • Stopping tenofovir-based PrEP in chronic hepatitis B needs a liver-monitoring plan.
  • PrEP prevents HIV but does not prevent other STIs or pregnancy.
sources for this section:Canadian HIV PrEP/PEP 2025

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian HIV PrEP/PEP 2025

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian HIV PrEP/PEP 2025

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. CIHR Pan-Canadian Network for HIV/AIDS and STBBI Clinical Trials ResearchCanadian guideline on HIV pre- and postexposure prophylaxis: 2025 updateaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.